R&D
Therapeutics
Microbiome Therapeutics Pipeline - MASH
Pipeline
Indication
Discovery
Preclinical
Clinical Development
Phase1
Phase2
Phase3
LABTHERA-006
Metabolic Dysfunction–Associated Steatohepatitis (MASH)
Metabolic dysfunction–associated steatohepatitis (MASH) is a progressive liver disease characterized by hepatic fat accumulation and inflammation driven by metabolic disorders such as obesity and diabetes. MASH represents a more advanced stage than simple steatosis and can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma.
The gut microbiome is closely linked to liver health through the gut–liver axis.
In MASH, microbiome dysbiosis alters metabolic profiles and promotes lipid accumulation and inflammatory responses in the liver, contributing to disease progression.
In MASH, microbiome dysbiosis alters metabolic profiles and promotes lipid accumulation and inflammatory responses in the liver, contributing to disease progression.
LABTHERA-006 is a microbiome-based therapeutic candidate that demonstrated significant inhibition of hepatic fat accumulation, inflammation, and fibrosis, along with improvement of hyperlipidemia, in both high-fat/high-fructose/high-cholesterol and high-fat/high-fructose diet–induced MASH animal models.
Treatment with LABTHERA-006 also resulted in favorable modulation of gut microbiome composition in these models, supporting its mechanism of action through microbiome regulation.
Treatment with LABTHERA-006 also resulted in favorable modulation of gut microbiome composition in these models, supporting its mechanism of action through microbiome regulation.
Based on these findings, LABTHERA-006 is expected to offer a differentiated microbiome-based therapeutic approach for MASH by targeting the gut–liver axis to prevent disease progression and promote liver health.